Your Cart is Empty
Start shopping
Euflexxa vs Orthovisc is a common comparison for clinicians and patients considering hyaluronic acid injections for knee osteoarthritis. The need for effective knee osteoarthritis management is expected to grow, with global knee osteoarthritis cases projected to increase by approximately 74.9% between 2020 and 2050.[4] Both viscosupplements are intended to improve joint lubrication, reduce discomfort, and support mobility.
Although Euflexxa and Orthovisc serve the same general purpose, they differ in their molecular characteristics, treatment schedules, and how individual patients may respond. These distinctions can influence convenience, treatment planning, and product selection.
This article compares the two viscosupplements in terms of formulation, efficacy, safety, administration schedule, and real-world patient outcomes, helping clinicians and patients discuss which option may be more suitable for long-term osteoarthritis management.
Key Takeaways
- Euflexxa and Orthovisc are both FDA-approved hyaluronic acid injections used to treat knee osteoarthritis by improving joint lubrication and reducing pain without the use of steroids.
- Euflexxa offers a more uniform molecular structure with injections administered once a week for 3 weeks.
- Orthovisc, though formerly derived from rooster combs, is now made via bacterial fermentation and follows a weekly schedule for 3–4 weeks.
- Both products are well-tolerated, with minor and temporary side effects such as joint swelling, tenderness, and redness.
- They are suitable for patients with avian allergies and carry a low risk of systemic effects.
- Pros and cons come down to patient preference, treatment schedule, and prior insurance approval, rather than clinical efficacy, which is comparable between both.
- Treatment costs vary according to insurance coverage, prior-authorization requirements, provider and facility fees, and the number of injections prescribed. Patients should confirm whether a quoted amount covers one injection or the complete treatment series.
About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and a range of medical and aesthetic products for your practice. We offer authentic products from leading brands at the lowest prices. Contact Doctor Medica today!
Recommended products
Source Material and Molecular Characteristics
Euflexxa contains non-avian, bioengineered sodium hyaluronate with a molecular weight of approximately 2.4 million Daltons. Designed to mimic the natural viscosity of synovial fluid, it improves joint lubrication and shock absorption. Its origin via bacterial fermentation means a lower risk of allergic reactions, especially for patients with sensitivities to avian-based products or egg-derived compounds.
Orthovisc, now also derived from bacterial fermentation, was originally formulated using rooster combs, a fact that shaped early concerns about allergenicity. Its molecular weight range of 1.0–2.9 million Daltons gives it a thicker consistency than Euflexxa. Some clinicians suggest this increased viscosity may allow the product to remain longer in the joint space, potentially offering more persistent cushioning and relief.
Product selection also involves practical considerations beyond formulation and treatment scheduling. When licensed practices purchase Euflexxa online, sourcing it from a reputable medical supplier helps ensure product authenticity, proper handling, and greater confidence in the supplies used for patient care.
While both products simulate synovial fluid function, differences in molecular uniformity can affect how they feel once injected. Euflexxa’s consistent texture often allows for smoother joint motion, while Orthovisc’s thicker feel might provide extended joint coating.[1] Factors like previous response, physician guidance, and personal comfort can help determine which formulation is most suitable.
Euflexxa vs Orthovisc: Dosage Regimens and Clinical Workflow
Understanding injection schedules is essential when choosing a viscosupplement, particularly for patients balancing mobility, work, or limited access to care. Euflexxa is administered once weekly for three weeks, while Orthovisc is administered once weekly for a total of three or four injections.
| Feature | Euflexxa | Orthovisc |
| Injection Frequency | Once per week for 3 weeks | Once per week for 3–4 weeks |
| Total Treatment Duration | 3 weeks | 3-4 weeks |
| Clinic Visit Count | Weekly (3 visits) | Weekly (3–4 visits) |
| Monitoring Opportunities | Weekly follow-up and adjustment | |
| Best For | Fixed three-visit treatment schedule | Three- or four-visit treatment schedule |
| Potential Drawbacks | Requires consistent weekly visits | May extend treatment slightly |
Euflexxa follows a fixed three-injection schedule. Orthovisc may involve three or four weekly injections, so it can require the same number of clinic visits as Euflexxa or one additional visit.
The Euflexxa vs Orthovisc comparison shows that both treatments require weekly appointments. Euflexxa has a fixed three-visit schedule, while Orthovisc may require either three or four visits. Treatment selection should be based on the prescribed regimen, previous treatment response, insurance coverage, and clinician guidance.
Efficacy Outcomes and Patient Response
Evidence for viscosupplementation as a class remains mixed. A 2022 systematic review found a small average reduction in knee osteoarthritis pain compared with placebo, although the difference did not meet the review’s threshold for a clinically important benefit.[3] Because the analysis covered viscosupplements as a group, it does not establish whether Euflexxa or Orthovisc is more effective.
Euflexxa typically provides benefit within 2–4 weeks, with peak relief around week 6, and effects lasting up to 6 months. Orthovisc, with its broader molecular profile, may peak slightly later—around week 8—with relief extending 5 to 6 months.
Patient response can also vary according to baseline osteoarthritis severity. A secondary analysis of the FLEXX trial and its extension found that patients with less severe radiographic knee osteoarthritis generally experienced greater benefit from Euflexxa than those with more advanced radiographic changes. However, some patients with more severe disease showed a better response after a second treatment course.[2]
Individual responses are why discussing the pros and cons of Euflexxa and Orthovisc with your provider is critical in selecting the best product for long-term OA care.
Adverse Events and Allergy Risk
Both products have strong safety records, but understanding their side effect profiles helps with patient counseling and planning.
Common Side Effects
- Pain, swelling, or tenderness in the treated knee
- Warmth or stiffness after injection
- Mild fluid buildup or redness at the site
These effects are generally mild and resolve within 48–72 hours. Cold compresses and rest usually suffice.
Allergy & Systemic Considerations
- Euflexxa, made via bacterial fermentation, avoids animal-derived proteins, making it ideal for those with egg or bird allergies
- Orthovisc, although formerly avian-based, is now also made through bacterial fermentation, minimizing allergenic potential
- Neither product contains steroids, so there’s no immunosuppression, making them safer for patients with autoimmune or endocrine disorders
Both are well tolerated by individuals seeking steroid-free joint support and offer a favorable safety profile for long-term OA treatment.
Cost, Insurance, and Patient Preference
Cost is a significant factor when choosing a viscosupplement. The amount a patient pays may depend on insurance coverage, prior-authorization requirements, the number of injections prescribed, and clinician or facility fees. Patients should request an estimate for the complete treatment course and confirm whether administration charges are included.
Euflexxa requires three weekly appointments. Orthovisc also uses weekly intervals but may require three or four appointments, depending on the prescribed treatment course. The additional possible visit may affect total administration costs and scheduling.
Availability also matters. Some clinics stock only one brand based on supply contracts, insurance relationships, or clinician preference.
Conclusion
Comparing Euflexxa vs Orthovisc reveals that both are FDA-approved, effective, and safe viscosupplements for managing knee osteoarthritis. They share similar goals—pain reduction, improved mobility, and steroid-free symptom control—but differ in formulation, viscosity, and treatment feel.
The choice between them often depends more on patient-specific needs, such as scheduling, insurance coverage, and individual response, than on overall efficacy. Discussing your treatment goals with your provider and considering cost, convenience, and allergy concerns will help identify the most appropriate solution.
FAQs
1. Is one product better at delaying knee replacement?
Both offer significant pain relief and improved joint function, delaying more aggressive treatments, but neither has proven superiority in preventing the need for surgical intervention.
2. Can I switch between Euflexxa and Orthovisc?
Yes, switching is possible, often guided by patient response and preference. Always consult your provider about timing and joint preparation for crossover.
3. Are there differences in side effects?
Side effect profiles are similar, with mild pain, swelling, or redness. Neither product suppresses the immune system nor risks cartilage damage.
4. How much does each series cost?
There is no single standard patient cost for an Euflexxa or Orthovisc treatment series. Costs vary according to insurance coverage, provider and facility charges, location, and the number of injections prescribed. Patients should confirm whether an estimate covers one injection or the complete treatment course.
Citations
[1] Altman, Roy D et al. “A double-blind, randomized, saline-controlled study of the efficacy and safety of EUFLEXXA for treatment of painful osteoarthritis of the knee, with an open-label safety extension (the FLEXX trial).” Seminars in arthritis and rheumatism vol. 39,1 (2009): 1-9. doi:10.1016/j.semarthrit.2009.04.001
[2] Altman, Roy D et al. “Analysis for Prognostic Factors from a Database for the Intra-Articular Hyaluronic Acid (Euflexxa) Treatment for Osteoarthritis of the Knee.” Cartilage vol. 7,3 (2016): 229-37. doi:10.1177/1947603515620890
[3] Pereira, Tiago V et al. “Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.” BMJ (Clinical research ed.) vol. 378 e069722. 6 Jul. 2022, doi:10.1136/bmj-2022-069722
[4] GBD 2021 Osteoarthritis Collaborators. “Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021.” The Lancet. Rheumatology vol. 5,9 e508-e522. 21 Aug. 2023, doi:10.1016/S2665-9913(23)00163-7
The content on this page has been written and fact-checked in accordance with our Editorial Policy. Clinical claims are sourced from peer-reviewed literature, regulatory documentation, and manufacturer specifications. Where citations are provided, it is always in accordance to our editorial standards.